CSL (CSLLY) Tariff Resilience Score: 7/10 (As of Jun. 27, 2026)


CSLLY CSL Ltd CSLLY
73 GF Score
Price $19.98
GF Value $50.49
Valuation Significantly Undervalued
! 7 Warning Signs
View Full Analysis

What is CSL Tariff Resilience Score?

CSL CSLLY -2.30% 73 Tariff Resilience Score is 7 as of Jun. 27, 2026. GuruFocus rates CSLLY with a GF Score™ of 73/100 and a GF Value™ of $50.49 (Significantly Undervalued). The stock has 7 warning signs investors should review. Among 1,378 Biotechnology companies, CSL ranks better than 90.42% on this metric.

CSL has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

CSL has CSL Ltd has a global presence with diversified manufacturing and sales. While it faces some tariff exposure, its strong market position and ability to adjust supply chains enhance resilience. The healthcare industry often benefits from tariff exemptions.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes CSL might have Highly Resilient.

CSL  (OTCPK:CSLLY) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

CSL Tariff Resilience Score Related Terms

CSLLY vs VRTX, REGN, ALNY: Tariff Resilience Score Comparison

For the Biotechnology subindustry, CSL's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CSL Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CSL's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where CSL's Tariff Resilience Score falls into.


CSLLY
73GF Score
CSL Ltd CSLLY
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
CSL (CSLLY) has a Tariff Resilience Score of 7 as of Jun. 27, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, CSL ranks #132 out of 1378 companies in the Biotechnology industry, placing it in the top 9.6%.
Is CSL's Tariff Resilience Score too high?
CSL's current Tariff Resilience Score is 7. The Biotechnology industry median Tariff Resilience Score is 4.00. CSL's value of 7 is 75% above this industry median. Based on the distribution chart, CSL ranks #132 out of 1378 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, CSL has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CSL's Tariff Resilience Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CSL ranks #132 out of 1378 companies for Tariff Resilience Score. This places CSL in the top 10% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. CSL's value of 7 is 75% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,378 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CSL's current Tariff Resilience Score of 7 is 75% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CSL's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CSL stock overvalued right now?
Based on GuruFocus' analysis, CSL (CSLLY) is currently considered Significantly Undervalued. The stock's GF Value™ is $50.49, compared to a current price of $19.98 — trading 60.4% below its estimated fair value. The current Tariff Resilience Score is 7 and 75% above the Biotechnology industry median of 4.00. CSL's overall GF Score™ is 73/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For CSL (CSLLY), the current Tariff Resilience Score is 7 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CSL (CSLLY) Overvalued in 2026?

Based on GuruFocus' analysis, CSL stock appears to be undervalued. The current stock price of $19.98 is trading 60.4% below its estimated GF Value™ of $50.49. GuruFocus considers CSL to be Significantly Undervalued.

Key valuation signals for CSLLY:

  • Tariff Resilience Score: 7
  • GF Value™: $50.49 vs. price of $19.98 (60.4% below fair value)
  • GF Score™: 73/100 with 7 warning signs
  • Industry Position: 75% above the Biotechnology median (#132 of 1378)

No single metric tells the full story. See the CSLLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CSL Business Description

Address 655 Elizabeth Street, Melbourne, VIC, AUS, 3000
CSL is one of the largest global biotech companies and has three main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world's second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.
73GF Score

Get the complete analysis for CSLLY

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$19.98
Price
$50.49
GF Value